These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30324343)

  • 41. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer.
    Thol F; Gairing SJ; Czauderna C; Thomaidis T; Gamstätter T; Huber Y; Vollmar J; Lorenz J; Michel M; Bartsch F; Müller L; Kloeckner R; Galle PR; Wörns MA; Marquardt JU; Moehler M; Weinmann A; Foerster F
    JHEP Rep; 2022 Mar; 4(3):100417. PubMed ID: 35141511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
    Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
    Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
    Filippi R; Montagnani F; Lombardi P; Fornaro L; Aprile G; Casadei-Gardini A; Faloppi L; Palloni A; Satolli MA; Scartozzi M; Citarella F; Lutrino SE; Vivaldi C; Silvestris N; Rovesti G; Rimini M; Aglietta M; Brandi G; Leone F
    Acta Oncol; 2021 Oct; 60(10):1317-1324. PubMed ID: 34282710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as 
Second-line Treatment for Small Cell Lung Cancer].
    Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.
    Goktas Aydin S; Cakan Demirel B; Bilici A; Topcu A; Aykan MB; Kahraman S; Akbıyık I; Atci MM; Olmez OF; Yaren A; Sendur MAN; Geredeli C; Seker M; Urun Y; Karadurmus N; Aydin A
    Curr Med Res Opin; 2022 Oct; 38(10):1751-1758. PubMed ID: 35916475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
    Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Clin Oncol (R Coll Radiol); 2012 Mar; 24(2):105-11. PubMed ID: 21382702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic impact of lung recurrence in patients with biliary tract cancer.
    Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Serikawa M; Ishii Y; Arihiro K; Murakami Y; Murashita J; Takahashi S
    Langenbecks Arch Surg; 2023 Jul; 408(1):290. PubMed ID: 37522989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.
    Rovesti G; Leone F; Brandi G; Fornaro L; Scartozzi M; Niger M; Yoo C; Caputo F; Filippi R; Casagrande M; Silvestris N; Santini D; Faloppi L; Palloni A; Aglietta M; Vivaldi C; Cho H; Lai E; Fenocchio E; Nichetti F; Pella N; De Lorenzo S; Di Maio M; Vasile E; de Braud F; Jeong JH; Aprile G; Orsi G; Cascinu S; Casadei-Gardini A
    J Gastrointest Cancer; 2022 Jun; 53(2):289-298. PubMed ID: 33544375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis.
    Morino K; Seo S; Yoh T; Fukumitsu K; Ishii T; Taura K; Morita S; Kaido T; Uemoto S
    Ann Surg Oncol; 2020 Jun; 27(6):1908-1917. PubMed ID: 31939034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature.
    Miyazaki Y; Kokudo T; Amikura K; Kageyama Y; Takahashi A; Ohkohchi N; Sakamoto H
    Jpn J Clin Oncol; 2017 Mar; 47(3):206-212. PubMed ID: 27940488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.
    Rizzo A; Salati M; Frega G; Merz V; Caputo F; Di Federico A; Palloni A; Carloni R; Ricci AD; Gadaleta-Caldarola G; Messina C; Spallanzani A; Gelsomino F; Benatti S; Luppi G; Melisi D; Dominici M; Brandi G
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis.
    Wang F; Wang FH; Sun K; Jiang C; Peng S; Xu LX; Kuang M; Guo GF; Chen SL
    J Inflamm Res; 2022; 15():6031-6046. PubMed ID: 36339826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of sex in the outcomes of patients with biliary tract cancers remains unclear: A population-based study.
    Lemke M; DeWit Y; Nanji S; Booth CM; Flemming JA
    Am J Surg; 2018 Dec; 216(6):1118-1121. PubMed ID: 29934122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Completion of adjuvant S-1 chemotherapy after surgical resection for biliary tract cancer: A single center experience.
    Iwaki K; Yoh T; Nishino H; Nishio T; Koyama Y; Ogiso S; Ishii T; Kanai M; Hatano E
    Asian J Surg; 2024 Mar; 47(3):1383-1388. PubMed ID: 38160154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic Impact of Sarcopenia in Patients With Biliary Tract Cancer Undergoing Chemotherapy.
    Meguro K; Hosono K; Sato M; Sugimoto Y; Takai Y; Kurita Y; Kanoshima K; Shimizu T; Sakai E; Nakajima A
    In Vivo; 2021; 35(5):2909-2915. PubMed ID: 34410986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index.
    Rovesti G; Leone F; Brandi G; Cesario S; Scartozzi M; Niger M; Yoo C; Filippi R; Casagrande M; Silvestris N; Santini D; Faloppi L; Palloni A; Aglietta M; Bernardini L; Cho H; Lai E; Fenocchio E; Pircher C; Iacono D; De Lorenzo S; Sperti E; Massa V; De Braud F; Jeong JH; Aprile G; Burgio V; Cascinu S; Casadei-Gardini A
    J Gastrointest Cancer; 2022 Sep; 53(3):528-536. PubMed ID: 34033000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
    Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Jin MH; Oh KS; Kim JM; Kim TY; Oh DY
    Liver Int; 2021 Feb; 41(2):388-395. PubMed ID: 32780918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Second-line chemotherapy in advanced biliary cancer: the present now will later be past.
    Vivaldi C; Fornaro L; Cereda S; Aprile G; Santini D; Silvestris N; Lonardi S; Leone F; Milella M; Brandi G; Vasile E
    Ann Oncol; 2014 Dec; 25(12):2443-2444. PubMed ID: 25122694
    [No Abstract]   [Full Text] [Related]  

  • 60. Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer.
    Park CS; Sung MJ; Kim SJ; Jo JH; Lee HS; Chung MJ; Bang S; Park SW; Song SY; Park JY
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.